Disclosures for "A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab to Prevent Relapses in Neuromyelitis Optica Spectrum Disorder (NMOSD)"